A systematic review on the economic burden of interstitial lung disease and the cost-effectiveness of current therapies.
Costs and cost analysis
Lung diseases, interstitial
Journal
BMC pulmonary medicine
ISSN: 1471-2466
Titre abrégé: BMC Pulm Med
Pays: England
ID NLM: 100968563
Informations de publication
Date de publication:
20 Apr 2022
20 Apr 2022
Historique:
received:
20
12
2021
accepted:
18
03
2022
entrez:
21
4
2022
pubmed:
22
4
2022
medline:
23
4
2022
Statut:
epublish
Résumé
The economic burden of interstitial lung disease (ILD) is unknown, limiting informed resource allocation and planning. We sought to conduct the first systematic review on the direct, indirect, and overall costs associated with ILD and to evaluate the cost-effectiveness of current therapies globally. We conducted systematic reviews of ILD disease cost studies and cost-effectiveness analyses (CEAs) using MEDLINE, Embase, and Web of Science databases between 2000 and 2020. We compared ILD costs between countries according to the share of costs towards each country's respective gross domestic product (GDP) per capita. Costs are reported in 2020 USD. We identified 25 disease cost studies and 7 CEAs. The direct medical costs ranged between $1824 and $116,927 annually per patient (median $32,834; 14-180% of GDP per capita in Western countries). The leading drivers of direct costs were inpatient (55%), outpatient (22%), and medication costs (18%), based on pooled estimates. Annual indirect costs ranged from $7149 to $10,902 per employed patient (median $9607; 12-23% of GDP per capita). Among the 7 CEAs, only 1 study (14%) showed an ILD therapy (ambulatory oxygen) was cost-effective compared to best supportive care. The direct and indirect costs associated with ILD are consistently high in all countries with available data, with cost-effectiveness profiles of new therapies generally undesirable. Globally, the median total direct cost for ILD equates to 51% of a country's GDP per capita and has been increasing over time.
Sections du résumé
BACKGROUND
BACKGROUND
The economic burden of interstitial lung disease (ILD) is unknown, limiting informed resource allocation and planning. We sought to conduct the first systematic review on the direct, indirect, and overall costs associated with ILD and to evaluate the cost-effectiveness of current therapies globally.
METHODS
METHODS
We conducted systematic reviews of ILD disease cost studies and cost-effectiveness analyses (CEAs) using MEDLINE, Embase, and Web of Science databases between 2000 and 2020. We compared ILD costs between countries according to the share of costs towards each country's respective gross domestic product (GDP) per capita. Costs are reported in 2020 USD.
RESULTS
RESULTS
We identified 25 disease cost studies and 7 CEAs. The direct medical costs ranged between $1824 and $116,927 annually per patient (median $32,834; 14-180% of GDP per capita in Western countries). The leading drivers of direct costs were inpatient (55%), outpatient (22%), and medication costs (18%), based on pooled estimates. Annual indirect costs ranged from $7149 to $10,902 per employed patient (median $9607; 12-23% of GDP per capita). Among the 7 CEAs, only 1 study (14%) showed an ILD therapy (ambulatory oxygen) was cost-effective compared to best supportive care.
CONCLUSION
CONCLUSIONS
The direct and indirect costs associated with ILD are consistently high in all countries with available data, with cost-effectiveness profiles of new therapies generally undesirable. Globally, the median total direct cost for ILD equates to 51% of a country's GDP per capita and has been increasing over time.
Identifiants
pubmed: 35443657
doi: 10.1186/s12890-022-01922-2
pii: 10.1186/s12890-022-01922-2
pmc: PMC9020025
doi:
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
148Subventions
Organisme : National University of Singapore Start-up Grant
ID : (R-608-000-329-133)
Informations de copyright
© 2022. The Author(s).
Références
Can J Psychiatry. 2008 Apr;53(4):267-74
pubmed: 18478830
ERJ Open Res. 2018 May 25;4(2):
pubmed: 29850467
Health Technol Assess. 2015 Mar;19(20):i-xxiv, 1-336
pubmed: 25760991
BMJ. 1993 Sep 25;307(6907):793-5
pubmed: 8219957
Am J Respir Crit Care Med. 2000 Feb;161(2 Pt 1):646-64
pubmed: 10673212
BMC Pulm Med. 2016 Jan 05;16:2
pubmed: 26732054
Chest. 2020 Jun;157(6):1522-1530
pubmed: 32004554
Adv Ther. 2019 May;36(5):1100-1113
pubmed: 30929184
Eur Respir J. 2019 Sep 5;54(3):
pubmed: 31221807
Expert Rev Pharmacoecon Outcomes Res. 2008 Apr;8(2):165-78
pubmed: 20528406
BMC Pulm Med. 2019 Jan 10;19(1):11
pubmed: 30630460
PLoS One. 2021 Mar 18;16(3):e0247316
pubmed: 33735247
J Rheumatol. 2019 Apr;46(4):360-369
pubmed: 30442831
BMJ Open. 2017 Feb 13;7(2):e013156
pubmed: 28193850
N Engl J Med. 2014 Aug 28;371(9):796-7
pubmed: 25162885
PLoS Med. 2017 Jan 3;14(1):e1002191
pubmed: 28045908
Ann Am Thorac Soc. 2015 Jul;12(7):981-7
pubmed: 25923447
Health Policy Plan. 2017 Feb;32(1):141-145
pubmed: 27452949
Ann Am Thorac Soc. 2018 Mar;15(3):348-356
pubmed: 29323930
Clin Chest Med. 2012 Mar;33(1):41-50
pubmed: 22365244
Chest. 2019 Nov;156(5):887-895
pubmed: 31051170
Arch Bronconeumol. 2015 Jun;51(6):261-7
pubmed: 25454902
Clinicoecon Outcomes Res. 2018 Feb 22;10:127-137
pubmed: 29503576
Health Qual Life Outcomes. 2003 Dec 19;1:80
pubmed: 14687421
Eur Respir J. 2020 Feb 6;55(2):
pubmed: 31699838
BMC Pulm Med. 2020 Jul 11;20(1):188
pubmed: 32652979
Pharmacoeconomics. 2017 Apr;35(4):479-491
pubmed: 28039616
Lancet Respir Med. 2020 Feb;8(2):147-157
pubmed: 31578169
Int J Tuberc Lung Dis. 2017 Feb 1;21(2):230-235
pubmed: 28234090
J Rheumatol. 2018 Feb;45(2):235-241
pubmed: 29142033
Curr Med Res Opin. 2018 Oct;34(10):1731-1740
pubmed: 29368948
Ann Am Thorac Soc. 2020 Sep;17(9):1077-1084
pubmed: 32437249
Eur J Health Econ. 2013 Jun;14(3):367-72
pubmed: 23526140
Pharmacoeconomics. 2008;26(9):733-44
pubmed: 18767894
Respir Med. 2019 Jun;152:25-31
pubmed: 31128606
J Med Econ. 2017 May;20(5):518-524
pubmed: 28092235
Ann Am Thorac Soc. 2020 Jun;17(6):706-713
pubmed: 32197048
Rheumatology (Oxford). 2020 Aug 1;59(8):1878-1888
pubmed: 31740961
Pharmacoeconomics. 1993 Nov;4(5):353-65
pubmed: 10146874
BMJ. 1993 Sep 11;307(6905):670-3
pubmed: 8401057
Chest. 2013 Apr;143(4):1078-1084
pubmed: 23188187
Pharmacoecon Open. 2020 Sep;4(3):449-458
pubmed: 31939146
J Manag Care Spec Pharm. 2016 Apr;22(4):414-23
pubmed: 27023695
Am J Respir Crit Care Med. 2013 Sep 15;188(6):733-48
pubmed: 24032382
PLoS One. 2017 Jan 18;12(1):e0166462
pubmed: 28099456
Am J Transplant. 2004 Jul;4(7):1155-62
pubmed: 15196075
Adv Ther. 2020 May;37(5):2460-2476
pubmed: 32319038
N Engl J Med. 2019 Oct 31;381(18):1718-1727
pubmed: 31566307
J Mark Access Health Policy. 2019 Jun 24;7(1):1626171
pubmed: 31275535
J Med Econ. 2012;15(5):829-35
pubmed: 22455577
Value Health. 2017 Mar;20(3):496-506
pubmed: 28292496
Adv Ther. 2021 Feb;38(2):854-867
pubmed: 33315170